Search
Etrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigationalEtrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P1,4,5 with no detectable activity on S1P2 and S1P3 receptors. S1P receptors are membrane-derived lysophospholipid sig...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesAZD-1656
go.drugbank.com/drugs/DB14810InvestigationalAZD-1656 is under investigation in clinical trial NCT00747175 (A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes).
Ripretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigationalRipretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is ...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesEnsartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigationalNon-small cell lung cancer (NSCLC) is one of the most frequent subtypes of lung cancers and encompasses a variety of different lung cancers, with notable ones being adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Ensar...
Categories: P-glycoprotein substratesCefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigationalCefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics.[FDA Label] Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into...
Vibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigationalVibegron is a potent, selective beta-3 adrenergic receptor (β3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity. Vibegron was first approved in Japan in September 2018 for the treatment...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesJPC-3210
go.drugbank.com/drugs/DB15609ExperimentalJPC-3210 is a potent antimalarial agent. It is an erythrocytic schizonticide with potent in vitro antimalarial activity against multidrug-resistant Plasmodium falciparum lines, low cytotoxicity, potent in vivo efficacy against murine mal...
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP3A InhibitorsBrensocatib
go.drugbank.com/drugs/DB15638ApprovedNon-cystic fibrosis bronchiectasis (NCFB) is a chronic lung disease characterized by airway widening, mucus accumulation, and neutrophilic inflammation. Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor that inhibit...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InducersPralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigationalPralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expres...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesLecithin
go.drugbank.com/drugs/DB15834InvestigationalA complex mixture of phospholipids, glycolipids, triglycerides, phosphatidylcholines, phosphatidylethanolamines, and phosphatidylinositols.
Categories: P-glycoprotein substrates